Full-Time

Medical Science Liaison

Northeast Region

Confirmed live in the last 24 hours

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Biotechnology
Healthcare

Compensation Overview

$195k - $240kAnnually

+ Bonus + Equity Grant

Mid

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Advanced degree in health sciences (PharmD, M.D., or Ph.D. in a medically related field) preferred with 2-3 years of relevant experience in the hematologic malignancy therapeutic area and/or cell therapy is desired. Master’s degree in health sciences (RN, RPh, PA, NP, etc.) considered if extensive years of clinical and/or medical affairs experience in relevant therapeutic area is present.
  • 2+ years of experience in MSL/Medical Affairs in relevant therapeutic area.
  • Familiarity/experience with healthcare systems and access environments.
  • Demonstrated ability to partner, influence, and work successfully within and across functions and levels of leadership.
  • Excellence in communication and presentations skills with strong personal integrity.
  • Agile, adaptable, results orientated.
Responsibilities
  • Establish and maintain professional relationships with HCPs (MD, PA, NP, RN, PharmD) within the cell therapy and hematology space via both in-person and virtual interactions.
  • Develop and execute territory plans in alignment with Medical Affairs strategies, which includes interactions with academic thought leaders, disease state experts, cell therapy-referring HCPs, and community practices.
  • Compliantly partner with field-based teams to optimize HCP support and customer service.
  • Deliver approved medical and scientific education relevant to disease state and Arcellx products.
  • Share insights from external thought leaders and HCPs to inform the development of medical strategies and the development of future clinical programs.
  • Represent Arcellx at medical and scientific conferences.
  • Partner with clinical operations to support the execution of clinical trials.
  • Domestic travel of approximately 50-70% will be required and candidate would need to live within the territory.

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Company Stage

IPO

Total Funding

$194.5M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

18%

1 year growth

24%

2 year growth

72%
Simplify Jobs

Simplify's Take

What believers are saying

  • The Phase 3 iMMagine-3 trial for anito-cel could significantly boost Arcellx's market position if successful.
  • Recent robust long-term responses from the Phase 1 expansion trial of anito-cel indicate promising efficacy and safety, potentially leading to FDA approval.
  • The $285M equity investment and upfront cash from Kite provide substantial financial backing for Arcellx's ongoing and future projects.

What critics are saying

  • The competitive landscape for CAR T therapies is intense, with established players like Abecma and Carvykti posing significant challenges.
  • Regulatory hurdles, such as the recent FDA partial hold, could delay product development and market entry.

What makes Arcellx unique

  • Arcellx's anitocabtagene autoleucel (anito-cel) is the first BCMA CAR T therapy for multiple myeloma utilizing a novel D-Domain binder, setting it apart from existing treatments.
  • The company's strategic partnership with Kite, a Gilead Company, enhances its research capabilities and market reach, distinguishing it from smaller biotech firms.
  • Arcellx's focus on innovative immunotherapies for cancer and other incurable diseases positions it uniquely in the biotech landscape.

Help us improve and share your feedback! Did you find this helpful?